2025-04-28 10:30Financial Performance - The company's revenue for Q1 2025 reached ¥9,654,595,304.28, representing a 20.96% increase compared to ¥7,981,934,236.96 in the same period last year[6] - Net profit attributable to shareholders was ¥3,671,960,950.47, marking an 89.06% increase from ¥1,942,210,693.65 year-over-year[6] - Basic earnings per share rose to ¥1.29, a 92.54% increase from ¥0.67 in the previous year[6] - Total operating revenue for Q1 2025 reached ¥9,654,595,304.28, an increase of 21% compared to ¥7,981,934,236.96 in Q1 2024[21] - Net profit for Q1 2025 was ¥3,715,468,841.04, up 90% from ¥1,958,853,204.95 in Q1 2024[21] - Operating profit for Q1 2025 was ¥4,292,748,775.29, compared to ¥2,309,847,178.76 in Q1 2024, reflecting a growth of 86%[21] - The total comprehensive income for Q1 2025 was RMB 3,696.7 million, compared to RMB 1,745.1 million in Q1 2024, marking a 111.5% increase[29] - The company reported a gross profit of RMB 4,013.1 million for Q1 2025, compared to RMB 3,005.7 million in Q1 2024, reflecting a 33.4% increase[27] - The operating profit for Q1 2025 was RMB 4,158.9 million, significantly higher than RMB 2,324.9 million in Q1 2024, representing a 78.9% increase[27] Cash Flow and Investments - The net cash flow from operating activities was ¥3,195,429,861.72, up 41.57% from ¥2,257,117,807.86 in the same period last year[6] - The net cash flow from operating activities for Q1 2025 was RMB 3,195.4 million, compared to RMB 2,257.1 million in Q1 2024, reflecting a 41.5% increase[25] - The net cash flow from investing activities for Q1 2025 was RMB 2,199.8 million, a significant recovery from a negative RMB 854.4 million in Q1 2024[25] - The company reported a net cash inflow from investing activities of CNY 2,366.4 million in Q1 2025, compared to a net outflow of CNY 734.6 million in Q1 2024[33] Assets and Liabilities - The total assets at the end of the reporting period were ¥84,512,088,093.23, a 5.21% increase from ¥80,325,824,408.75 at the end of the previous year[6] - Total assets as of March 31, 2025, amounted to ¥84,512,088,093.23, an increase from ¥80,325,824,408.75 at the end of 2024[19] - Total liabilities increased to ¥21,733,326,335.92 from ¥21,240,210,773.18, indicating a rise of approximately 2.3%[19] - The total liabilities as of March 31, 2025, were CNY 21,733.3 million, slightly up from CNY 21,240.2 million as of December 31, 2024[31] - The total equity attributable to shareholders increased to ¥62,332,382,757.11 from ¥58,632,715,174.37, reflecting a growth of 6%[19] - The company’s total equity as of March 31, 2025, was CNY 62,778.8 million, an increase from CNY 59,085.6 million as of December 31, 2024[31] Business Segments and Growth - The company reported a significant increase in the chemical business revenue, which reached ¥739,097.03, up 32.87% from ¥556,262.85 in Q1 2024[9] - The chemical business generated revenue of RMB 7.39 billion, reflecting a year-on-year increase of 32.9%[10] - The small molecule D&M business reported revenue of RMB 3.85 billion, a year-on-year growth of 13.8%, with a total pipeline of 3,393 molecules as of the end of the reporting period[11] - TIDES business revenue surged to RMB 2.24 billion, marking a year-on-year increase of 187.6%, with backlog orders up 105.5%[11] - The testing business generated revenue of RMB 1.29 billion, with laboratory analysis and testing services revenue at RMB 880 million, down 4.9% year-on-year[14] - The clinical CRO and SMO business reported revenue of RMB 410 million, a year-on-year decline of 2.2%, while SMO revenue grew by 5.5%[14] - The biological business achieved revenue of RMB 610 million, reflecting an 8.2% year-on-year increase, with in vitro screening platform revenue up 28.9%[14] Operational Efficiency and Future Plans - The company continues to optimize production processes and operational efficiency, enhancing overall profitability through growth in late-stage clinical and commercialization projects[6] - The company plans to enhance its peptide solid-phase synthesis capacity, expecting the total volume of reactors to exceed 100,000L by the end of 2025[11] - The company successfully synthesized and delivered over 460,000 new compounds in the past 12 months, a 6% increase year-on-year[11] Market Position and Reputation - The company maintains a strong reputation in the global pharmaceutical R&D industry, driven by its integrated CRDMO business model[4] - As of March 2025, the company's backlog for continuing operations reached RMB 52.33 billion, a year-on-year increase of 47.1%[10]